Immunomedics, Inc. (IMMU) Shares Bought by SG Americas Securities LLC

SG Americas Securities LLC lifted its stake in shares of Immunomedics, Inc. (NASDAQ:IMMU) by 27.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 26,350 shares of the biopharmaceutical company’s stock after purchasing an additional 5,631 shares during the quarter. SG Americas Securities LLC’s holdings in Immunomedics were worth $368,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the company. FMR LLC lifted its position in Immunomedics by 260.6% in the 2nd quarter. FMR LLC now owns 5,496,851 shares of the biopharmaceutical company’s stock valued at $48,537,000 after acquiring an additional 3,972,388 shares in the last quarter. State Street Corp lifted its position in Immunomedics by 37.2% in the 2nd quarter. State Street Corp now owns 4,818,847 shares of the biopharmaceutical company’s stock valued at $42,549,000 after acquiring an additional 1,305,298 shares in the last quarter. Vanguard Group Inc. lifted its position in Immunomedics by 2.4% in the 2nd quarter. Vanguard Group Inc. now owns 4,522,091 shares of the biopharmaceutical company’s stock valued at $39,930,000 after acquiring an additional 105,558 shares in the last quarter. Farallon Capital Management LLC lifted its position in Immunomedics by 1.7% in the 2nd quarter. Farallon Capital Management LLC now owns 4,227,500 shares of the biopharmaceutical company’s stock valued at $37,329,000 after acquiring an additional 72,500 shares in the last quarter. Finally, Palo Alto Investors LLC bought a new position in Immunomedics in the 2nd quarter valued at about $26,582,000. 76.32% of the stock is currently owned by institutional investors.

Shares of Immunomedics, Inc. (NASDAQ:IMMU) opened at $12.41 on Friday. The company has a debt-to-equity ratio of -0.29, a current ratio of 0.74 and a quick ratio of 0.74. Immunomedics, Inc. has a one year low of $3.30 and a one year high of $14.48.

IMMU has been the topic of several recent research reports. Jefferies Group set a $11.00 price target on shares of Immunomedics and gave the company a “buy” rating in a research report on Thursday, August 17th. BidaskClub raised shares of Immunomedics from a “hold” rating to a “buy” rating in a research report on Wednesday, August 23rd. Zacks Investment Research raised shares of Immunomedics from a “hold” rating to a “buy” rating and set a $15.00 price target on the stock in a research report on Wednesday, October 4th. Finally, ValuEngine lowered shares of Immunomedics from a “hold” rating to a “sell” rating in a research note on Monday, December 4th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the stock. Immunomedics presently has a consensus rating of “Buy” and an average target price of $15.33.

In other news, Director Venbio Select Advisor Llc acquired 1,150,000 shares of the firm’s stock in a transaction on Tuesday, November 14th. The stock was purchased at an average price of $10.39 per share, for a total transaction of $11,948,500.00. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Behzad Aghazadeh acquired 1,325,000 shares of the firm’s stock in a transaction on Wednesday, November 15th. The stock was purchased at an average price of $10.47 per share, with a total value of $13,872,750.00. The disclosure for this purchase can be found here. Company insiders own 6.60% of the company’s stock.

WARNING: This report was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this report on another website, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this report can be accessed at https://sportsperspectives.com/2017/12/15/immunomedics-inc-immu-shares-bought-by-sg-americas-securities-llc.html.

About Immunomedics

Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.

Want to see what other hedge funds are holding IMMU? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immunomedics, Inc. (NASDAQ:IMMU).

Institutional Ownership by Quarter for Immunomedics (NASDAQ:IMMU)

Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply